BiotechTube

Escitalopram + Bupropion XL

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar I Disorder

Conditions

Bipolar I Disorder

Trial Timeline

Nov 1, 2010 → May 20, 2020

NCT ID
NCT00958633

About Escitalopram + Bupropion XL

Escitalopram + Bupropion XL is a phase 3 stage product being developed by Lupin Limited for Bipolar I Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00958633. Target conditions include Bipolar I Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00958633Phase 3Terminated

Competing Products

20 competing products in Bipolar I Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85